Westpac Banking Corp Sells 4,384 Shares of Eli Lilly and Company $LLY

Westpac Banking Corp trimmed its position in shares of Eli Lilly and Company (NYSE:LLY) by 30.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,192 shares of the company’s stock after selling 4,384 shares during the period. Westpac Banking Corp’s holdings in Eli Lilly and Company were worth $7,776,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of LLY. Vanguard Group Inc. increased its holdings in Eli Lilly and Company by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 80,959,089 shares of the company’s stock worth $61,771,785,000 after acquiring an additional 551,659 shares during the last quarter. Laurel Wealth Advisors LLC boosted its position in Eli Lilly and Company by 78,621.2% during the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after purchasing an additional 11,537,661 shares during the period. Norges Bank purchased a new position in shares of Eli Lilly and Company in the second quarter worth about $8,827,714,000. Jennison Associates LLC raised its position in shares of Eli Lilly and Company by 4.3% in the second quarter. Jennison Associates LLC now owns 5,447,636 shares of the company’s stock valued at $4,246,596,000 after purchasing an additional 226,620 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Eli Lilly and Company by 2.0% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 5,359,653 shares of the company’s stock valued at $4,178,010,000 after buying an additional 103,119 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,030.30 on Thursday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. The company has a market cap of $971.95 billion, a PE ratio of 44.89, a price-to-earnings-growth ratio of 1.21 and a beta of 0.39. The stock has a 50-day moving average price of $1,054.25 and a 200-day moving average price of $924.46.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. During the same period last year, the firm posted $5.32 earnings per share. Eli Lilly and Company’s quarterly revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.7%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 30.15%.

Analysts Set New Price Targets

A number of research firms recently weighed in on LLY. National Bank Financial set a $1,286.00 price objective on shares of Eli Lilly and Company in a research note on Monday, December 1st. Daiwa Securities Group raised their price target on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Rothschild & Co Redburn boosted their price objective on Eli Lilly and Company from $775.00 to $830.00 and gave the company a “neutral” rating in a research note on Monday, January 26th. Wolfe Research increased their price objective on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a report on Wednesday, December 3rd. Finally, Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $1,229.33.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: ACHIEVE‑3 head‑to‑head Phase 3 data published in The Lancet show oral orforglipron (36 mg) produced larger A1C reductions and substantially greater weight loss versus oral semaglutide, and Lilly says it has filed orforglipron in 40+ countries with potential U.S. action for obesity in Q2 2026. Lilly press release on ACHIEVE-3
• Positive Sentiment: Royal Bank of Canada initiated coverage / upgraded Lilly to a “moderate buy,” reflecting bullish analyst conviction that new obesity and diabetes assets support upside. Street Insider
• Positive Sentiment: Truist reaffirmed a buy rating on LLY after the head‑to‑head results, which can help underpin investor sentiment. MarketScreener
• Neutral Sentiment: Reuters published additional trial details highlighting the safety/side‑effect profile from the orforglipron vs oral semaglutide diabetes study — more safety detail lowers binary regulatory uncertainty but could raise monitoring in early commercialization. Reuters
• Neutral Sentiment: Bank of America tells investors Novo’s announced GLP‑1 list‑price cuts are unlikely to meaningfully dent U.S. market dynamics for rivals like Lilly, which tempers downside risk from competitor pricing moves. Yahoo / BofA coverage
• Negative Sentiment: Sector pressure from Novo Nordisk’s plan to cut U.S. list prices for Ozempic/Wegovy (reports of up to ~50% reductions) has already pressured GLP‑1 stocks; pricing moves raise the possibility of margin and competitive pricing pressure across the class. Yahoo: Novo halves US price

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.